Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 1;57(Supplement_2):S161-S167.
doi: 10.1093/mmy/myy067.

Beyond tissue concentrations: antifungal penetration at the site of infection

Affiliations
Review

Beyond tissue concentrations: antifungal penetration at the site of infection

Yanan Zhao et al. Med Mycol. .

Abstract

Despite advances in antifungal therapy, invasive fungal infections remain a significant cause of morbidity and mortality worldwide. One important factor contributing to the relative ineffectiveness of existing antifungal drugs is insufficient drug exposure at the site of infection. Despite the importance of this aspect of antifungal therapy, we generally lack a full appreciation of how antifungal drugs distribute, penetrate, and interact with their target organisms in different tissue subcompartments. A better understanding of drug distribution will be critical to guide appropriate use of currently available antifungal drugs, as well as to aid development of new agents. Herein we briefly review current perspectives of antifungal drug exposure at the site of infection and describe a new technique, matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging, which has the potential to greatly expand our understanding of drug penetration.

Keywords: MALDI imaging; antifungals; drug quantification; posaconazole; site of infection; tissue penetration.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Workflow of tissue drug exposure analysis by integrating MALDI imaging with LCM directed LC-MS/MS. This Figure is reproduced in color in the online version of Medical Mycology.
Figure 2.
Figure 2.
Close up examination of drug penetration for micafungin at 24 h, and CD101 at 6 and 48 h post single dosing. Enlarged view of drug distribution in a single lesion at pixel level. Matched GMS staining of adjacent sections was placed on the bottom. Signal intensity is fixed for CD101 and micafungin, respectively. Scale bars, 5 mm. Figure reprinted by permission: Zhao et al.Antimicrob Agents Chemother. 2017; 61: e01009-17. Copyright (2017) American Society for Microbiology (ASM). This Figure is reproduced in color in the online version of Medical Mycology.
Figure 3.
Figure 3.
MALDI imaging analysis of posaconazole and phosphatidylcholine (32:1) distribution in mouse lung infected with A. fumigatus embedded agar beads and collected at 4 h post two doses of posaconazole at 20 mg/kg. Images from left to right were acquired from the same tissue section: optical scan, ion map of posaconazole (m/z 701.337), ion map of phosphatidylcholine 32:1 (PC) (m/z 732.552), and corresponding overlay. Signal intensity color bar is fixed for posaconazole (red) and PC (green), respectively, with gradually increased intensity from black (no signal) to red or green (max signal). Yellow Outlines highlight one typical lesion formed with the A. fumigatus agar beads. This Figure is reproduced in color in the online version of Medical Mycology.

Similar articles

Cited by

References

    1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012; 4: 165rv113. - PubMed
    1. Pappas PG, Kauffman CA, Andes D et al. . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48: 503–535. - PMC - PubMed
    1. Pappas PG, Kauffman CA, Andes DR et al. . Executive summary: Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62: 409–417. - PubMed
    1. Heidelberger C, Chaudhuri NK, Danneberg P et al. . Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957; 179: 663–666. - PubMed
    1. Grunberg E, Titsworth E, Bennett M. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda). 1963; 161: 566–568. - PubMed

MeSH terms

Substances